# OnCo record paper-brentuximab-relapsed-salcl-five-year-blood-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-brentuximab-relapsed-salcl-five-year-blood-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-brentuximab-relapsed-salcl-five-year-blood-2017" ;
  schema:name "Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma"@en ;
  schema:alternateName "Pro 2017"@en ;
  schema:description "Six years after brentuximab vedotin for relapsed anaplastic large cell lymphoma, no one in the study had progressed after 40 months, and one in seven was still in remission with no further treatment of any kind."@en ;
  schema:url <https://onco.cc/key-papers/paper-brentuximab-relapsed-salcl-five-year-blood-2017/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://doi.org/10.1182/blood-2017-05-780049>, <https://pubmed.ncbi.nlm.nih.gov/28974506/>, <https://europepmc.org/article/MED/28974506> ;
  onco:tag "lymphoma-evidence-entities" ;
  schema:sameAs <https://doi.org/10.1182/blood-2017-05-780049> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Pro B, Advani R, Brice P, et al." ;
  onco:cancers <https://onco.cc/cancers/alk-positive-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/alk-negative-anaplastic-large-cell-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/> ;
  onco:trials <https://onco.cc/trials/brentuximab-salcl-phase-2/> .